Degenerative Disc Disease – Pipeline Review, 2024

Degenerative disc disease also sometimes known as spondylosis, is associated with an age-related condition that when one or more of the discs between the vertebrae of the spinal column breaks down, causing pain. Other factors that lead to degenerative disc diseases are traumatic injuries that can lead to weakening and swelling of the disc, loss of fluids in the disc due that gradually occurs due to aging, and sport & daily activities can cause the tears in the outer core of the disc. According to the reports published in National Center for Biotechnology Information (NCBI) it was estimated that around 266 million individuals (3.63%) worldwide suffer from Lumbar degenerative spine disease (DSD) with lower back pain every year. Neurological & physical examination and computerized tomography (CT) scan or a magnetic resonance imaging (MRI) methods are used for the diagnosis of degenerative disc disease.

Treatment for degenerative disc disease varies from conservative therapies to surgical interventions aimed to relieve pain, maintain the normal function of the disc, and reduce the stress on the discs. Muscle relaxants, antidepressants, non-steroidal anti-inflammatory drugs, corticosteroids injections, and pain reliever are some of the medications involved in the treatment of degenerative disc disease. Non-surgical treatment methods involve transcutaneous electrical nerve stimulation (TENS) and ultrasound therapy. Discectomy & fusion, corpectomy, facetectomy, laminotomy, and spinal laminectomy are some of the surgical methods used for the treatment of degenerative disc disease. Additionally, physical therapy, massage therapy, and acupuncture are the methods that can aid in relieving the pain associated with degenerative disc disease.

Pharmaceutical companies, along with various research funded organizations, have been focusing on studying and developing new treatment options for degenerative disc disease. For instance; AMG0103, which is being studied by AnGes, Inc., is currently in phase-1 clinical trials used for the study of safety, tolerability and exploratory efficacy of targeted single injection of AMG0103 in subject with chronic discogenic lumbar back pain

At present, around 79% of the pipeline candidates for degenerative disc disease are in the phase-1, phase-2, and phase-3 stage.

Report Description

The report on ‘Degenerative Disc Disease – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for degenerative disc disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for degenerative disc disease.

The report on ‘Degenerative Disc Disease – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights about the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sourcesinclude global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products fordegenerative disc disease


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players about R&D for Degenerative disc disease


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary